慢性乙型肝炎感染患者的HBS Ag血清清除率和血清转化时间

StephenW

HBS Ag Seroclearance and Seroconversion Time in Patients With Chronic Hepatitis B Infection
Jila Masrour-Roudsari  1 , Mohammadreza Hasanjani-Roushan  2 , Yousef Yahyapour  2 , Rahim Barari-Savadkoohi  2 , Ali Bijani  3 , Farzin Sadeghi  4 , Mousa Mohammadnia-Afroozi  2
Affiliations
Affiliations

    1
    Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
    2
    Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
    3
    Social Determinants Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
    4
    Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

    PMID: 32509250 PMCID: PMC7265509 DOI: 10.22088/cjim.11.2.205

Abstract

Background: Hepatitis B Surface antigen (HBsAg) seroclearance and seroconversion (development of antibodies against HBsAg) can increases the survival of Chronic hepatitis B (CHB) patients. The aim of this study was to determine the percentage and timing of HBsAg seroclearance and seroconversion in patients with chronic hepatitis B infection.

Methods: 1026 patients with CHB infection who referred to a private clinic were included. These patients had been followed-up for an average of 15 years. The patients whose HBs Ag was cleared from the blood and remained negative until the end of follow-up were designated as HBs Ag serocleared and the patients whose HBs Ab was positive during follow-upwas designated as HBs Ag seroconverted. The time of seroclearance and seroconversion of patients was recorded. Liver function tests, alpha-fetoprotein (AFP) and Hepatitis B early antigen (HBe Ag) status were extracted from the patients' medical records. Data were analysis with SPSS 17.

Results: The duration of follow-up was from 2 to 410 months and most patients were males (58.2%).The survival rate of HBs Ag positivity after 5, 10 and 15 years were 95.6, 89.4 and 80.7%, and 98, 93.5 and 84.9% of patients had not yet developed anti-HBs antibodies after 5, 10 and 15 years, respectively. Age, gender and taking medication had no effect on HBs Ag clearance from the blood or anti-HBs production.

Conclusion: The HBs Ag seroconversion is a rare occurrence, but the incidence of this may increase with time, age and drug consumption. Though there was no relationship in our patients.

Keywords: Chronic Hepatitis B; Hepatitis B Surface antigen; Seroclearance; Seroconversion.

StephenW

慢性乙型肝炎感染患者的HBS Ag血清清除率和血清转化时间
吉拉·马斯鲁（Jila Masrour-Roudsari）1，穆罕默德扎（Mohammadreza Hasanjani-Roushan）2，优素福·雅哈普（Yousef Yahyapour）2，拉希姆·巴拉里（Rahim Barari-Savadkoohi）2，阿里·比贾尼（Ali Bijani）3，法尔辛·萨德吉（Farzin Sadeghi）4，穆萨·穆罕默德尼亚·阿夫鲁兹2
隶属关系
隶属关系

    1个
    巴博尔医科大学学生研究委员会，伊朗巴博尔。
    2
    巴博尔医科大学健康研究所传染病和热带医学研究中心，伊朗巴博尔。
    3
    巴博尔医科大学健康研究所社会决定因素研究中心，伊朗巴博尔。
    4
    巴博尔医科大学健康研究所细胞与分子生物学研究中心，伊朗巴博尔。

    PMID：32509250 PMCID：PMC7265509 DOI：10.22088 / cjim.11.2.205

抽象

背景：乙型肝炎表面抗原（HBsAg）的血清清除和血清转换（抗HBsAg抗体的开发）可以增加慢性乙型肝炎（CHB）患者的存活率。这项研究的目的是确定慢性乙型肝炎感染患者中HBsAg血清清除和血清转化的百分比和时间。

方法：纳入转诊至私人诊所的1026例CHB感染患者。这些患者平均随访了15年。 HBs Ag从血液中清除并在随访结束前保持阴性的患者被指定为HBs Ag血清清除，随访期间HBs Ab阳性的患者被称为HBs Ag血清转化。记录患者的血清清除和血清转化的时间。从患者的病历中提取肝功能检查，甲胎蛋白（AFP）和乙型肝炎早期抗原（HBe Ag）状态。使用SPSS 17分析数据。

结果：随访时间为2至410个月，大多数患者为男性（58.2％）。5、10和15年后HBs Ag阳性存活率分别为95.6、89.4和80.7％，98、93.5 5年，10年和15年后，分别有84.9％的患者尚未产生抗HBs抗体。年龄，性别和服用药物对血液中HBs Ag清除率或抗HBs产生均无影响。

结论：HBs Ag血清转化很少见，但其发生率可能随着时间，年龄和药物消耗的增加而增加。尽管我们的患者没有关系。

关键字：慢性乙型肝炎；乙型肝炎表面抗原；清除血清；血清转化